Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease

NCT03924414 is registered in ClinicalTrials.gov with California Pacific Medical Center Research Institute as lead sponsor.

NCT NCT03924414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03924414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease
Lead sponsor
California Pacific Medical Center Research Institute
Phase
Phase 4
Overall status
Completed
Start date
November 15, 2019
Completion date
February 28, 2026
Enrollment
2,721 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

atypical parkinsonism, dementia with lewy bodies, multiple system atrophy, osteoporosis, parkinson disease, parkinson's disease and parkinsonism, parkinsonism, progressive supranuclear palsy, vascular parkinsonism